Guggenheim analyst Etzer Darout lowered the firm’s price target on Inventiva (IVA) to $11 from $13 and keeps a Buy rating on the shares after updating the firm’s model to incorporate the announcement of $172.5M in equity financing, which the company plans to use to fund continuation of the NATiV3 Phase 3 trial, initiate the outcome trial, and for commercialization activities.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVA:
- Inventiva Secures $172.5M from Full Exercise of Underwriters’ Option
- Inventiva S.A. Announces $140 Million Public Offering of ADSs
- Inventiva 32.47M share Spot Secondary priced at $3.85
- Inventiva announves $125M American Depositary shares offering
- Inventiva S.A. Announces General Meeting for November 27, 2025